Frances Lee, MD

Frances Lee, MD, is an assistant professor of medicine in the division of liver diseases at Mount Sinai.

Articles by Frances Lee, MD

Binge Drinking Frequency Tied to Advanced Fibrosis in MetALD, ALD, With Frances Lee, MD

ByFrances Lee, MD

May 13th 2026

Lee discusess DDW 2026 data linking binge drinking frequency to advanced hepatic fibrosis in SLD.

Future Advancements in PBC Care: Innovations on the Horizon

ByFrances Lee, MD,Aparna Goel, MD,A. Sidney Barritt IV, MD, MSCR,Lance L. Stein, MD

March 2nd 2026

In the final episode, “Future Advancements in PBC Care: Innovations on the Horizon,” the panelists explore current gaps in care and new treatments that are trying to close those gaps.

New Fatigue Signals From Elafibranor: Results From the ELATIVE Phase III Trial

ByFrances Lee, MD,Aparna Goel, MD,A. Sidney Barritt IV, MD, MSCR,Lance L. Stein, MD

February 23rd 2026

New studies reveal potential benefits of alfagimor in reducing fatigue and pruritus, highlighting its role in second-line therapy for patients.

Addressing Fatigue: Traditional Management Outside Primary Therapy

ByFrances Lee, MD,Aparna Goel, MD,A. Sidney Barritt IV, MD, MSCR,Lance L. Stein, MD

February 23rd 2026

In this episode, experts delve into the limited treatment options to address the symptom of fatigue in patients with primary biliary cholangitis. They highlight how small changes, like regular sleep schedules and exercise, can improve fatigue.

The Safety of PPAR Agonists in PBC: Reviewing Recent Trial Data

ByFrances Lee, MD,Aparna Goel, MD,A. Sidney Barritt IV, MD, MSCR,Lance L. Stein, MD

February 16th 2026

Explore the safety and long-term effects of PPAR agonists in patients with liver disease, addressing concerns about bone health and medication interactions.

The Efficacy of PPAR Agonists in PBC: Signals of Extrahepatic Improvements

ByFrances Lee, MD,Aparna Goel, MD,A. Sidney Barritt IV, MD, MSCR,Lance L. Stein, MD

February 16th 2026

Explore the latest FDA-approved second-line therapies for PBC, including seladelpar and elafibranor, and their mechanisms of action.

How Special Populations and Disease Risk Impact Treatment Assessment in PBC

ByFrances Lee, MD,Aparna Goel, MD,A. Sidney Barritt IV, MD, MSCR,Lance L. Stein, MD

February 9th 2026

Healthcare professionals discuss individualized approaches to second-line therapy for liver disease, considering patient age, fibrosis, and insurance challenges.

Experts Review the First- and Second-Line Treatment Options for PBC

ByFrances Lee, MD,Aparna Goel, MD,A. Sidney Barritt IV, MD, MSCR,Lance L. Stein, MD

February 9th 2026

Experts discuss first-line treatments for Primary Biliary Cholangitis, emphasizing the importance of monitoring and patient compliance for effective management.

Diagnostic Criteria in PBC: What Clinicians are Looking For

ByFrances Lee, MD,Aparna Goel, MD,A. Sidney Barritt IV, MD, MSCR,Lance L. Stein, MD

February 2nd 2026

Learn how to diagnose Primary Biliary Cholangitis (PBC) through key criteria and the importance of specific autoantibodies in patient evaluation.

Assessing Disease Severity and Progression Risk in PBC

ByFrances Lee, MD,Aparna Goel, MD,A. Sidney Barritt IV, MD, MSCR,Lance L. Stein, MD

February 2nd 2026

Explore the complexities of Primary Biliary Cholangitis (PBC), including risk factors, disease progression, and essential comorbidities for effective management.

Key Symptoms of PBC- Fatigue, Pruritus, and Bone Health

ByFrances Lee, MD,Aparna Goel, MD,A. Sidney Barritt IV, MD, MSCR,Lance L. Stein, MD

January 26th 2026

Explore the complex relationship between pruritus, fatigue, and bone health in patients with primary biliary cholangitis (PBC).

An Overview of PBC Pathophysiology, Severity, and Burden

ByAparna Goel, MD,A. Sidney Barritt IV, MD, MSCR,Lance L. Stein, MD,Frances Lee, MD

January 26th 2026

Explore expert insights on primary biliary cholangitis, focusing on symptoms, treatment innovations, and emerging clinical data for effective patient management.

Closing Gaps in PBC Care With Emerging and Established Second-Line Treatments

ByFrances Lee, MD,A. Sidney Barritt, MD

January 22nd 2026

A pair of hepatology experts discuss the shifting therapeutic landscape in PBC, lingering unmet needs, and where the field may be heading next.

Addressing Stigma and Advancing Care in Alcohol-Associated Liver Disease, With Frances Lee, MD

ByFrances Lee, MD

January 15th 2026

Lee describes misconceptions about ALD, the importance of multidisciplinary care, and what the future of pharmacotherapy for this disease may hold.

Latest Updated Articles

Key Symptoms of PBC- Fatigue, Pruritus, and Bone Health
January 26th 2026
An Overview of PBC Pathophysiology, Severity, and Burden
January 26th 2026

Frances Lee, MD

Articles by Frances Lee, MD

Binge Drinking Frequency Tied to Advanced Fibrosis in MetALD, ALD, With Frances Lee, MD

Future Advancements in PBC Care: Innovations on the Horizon

New Fatigue Signals From Elafibranor: Results From the ELATIVE Phase III Trial

Addressing Fatigue: Traditional Management Outside Primary Therapy

The Safety of PPAR Agonists in PBC: Reviewing Recent Trial Data

The Efficacy of PPAR Agonists in PBC: Signals of Extrahepatic Improvements

How Special Populations and Disease Risk Impact Treatment Assessment in PBC

Experts Review the First- and Second-Line Treatment Options for PBC

Diagnostic Criteria in PBC: What Clinicians are Looking For

Assessing Disease Severity and Progression Risk in PBC

Key Symptoms of PBC- Fatigue, Pruritus, and Bone Health

An Overview of PBC Pathophysiology, Severity, and Burden

Closing Gaps in PBC Care With Emerging and Established Second-Line Treatments

Addressing Stigma and Advancing Care in Alcohol-Associated Liver Disease, With Frances Lee, MD

Latest Updated Articles

Trending on HCPLive

Diagnostic Pearls and New Therapies in Connective Tissue Disease, With Michelle Min, MD

Rethinking “Type 2”: Inside the 2026 AACE Diabetes Classification Algorithm

VIASKIN Peanut Patch Efficacy Holds in Kids With Atopic Comorbidities

Fezolinetant Shows No CNS Safety Signal in Pooled Analysis of 3100 Women, With Marla Shapiro, CM

CAPTAIN-T2D: Interim Results Display High Cortisol Prevalence in Difficult-to-Control T2D